1. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, and Takehara T
- Subjects
- Aged, Anemia chemically induced, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Dose-Response Relationship, Drug, Drug Eruptions etiology, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, Oligopeptides adverse effects, Oligopeptides therapeutic use, Polyethylene Glycols adverse effects, Prospective Studies, RNA, Viral blood, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Ribavirin adverse effects, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Oligopeptides administration & dosage, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Background: Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antiviral efficacy and safety in the reduced administration of TVR were examined., Methods: A total of 81 CH-C Japanese patients with HCV genotype 1 were randomized into two regimens of TVR 2250 mg (TVR-2250) or 1500 mg (TVR-1500) and treated with triple therapy for 24 weeks., Results: The mean HCV RNA at start, 2 and 4 weeks of treatment were 6.69 ± 0.70, 1.05 ± 0.74, 0.22 ± 0.48 log10 IU/ml in the TVR-2250 group and 6.70 ± 0.62, 1.02 ± 0.62, 0.13 ± 0.41 log10 IU/ml in the TVR-1500 group. The SVR rates were 85% in both groups (35/41 and 34/40, respectively). There were no patients with viral breakthrough in either group. As for adverse effects, rash more than moderate and severe anemia with <8.5 g/dl of hemoglobin were higher in the TVR-2250 group than in the TVR-1500 group (p = 0.046, p < 0.001, respectively). The increase in serum creatinine levels and decrease in estimated glomerular filtration rates were higher in the TVR-2250 group than in the TVR-1500 group., Conclusions: The lower dose of TVR (1500 mg/day) can result in similar SVR rates and lower treatment-related adverse effects compared to the higher dose of TVR (2250 mg/day) in triple therapy (UMIN: 000007313, 000007330).
- Published
- 2015
- Full Text
- View/download PDF